Active Pharmacovigilance Project on the safety profile of Dolutegravir in Brazil

References

• Batista, C., Correa, R. G., Evangelista, L. R., Fleck, K., Silva, L., Renaud, F., Vitoria, M., Doherty, M., & Benzaken, A. S. (2019). The Brazilian experience of implementing the active pharmacovigilance of dolutegravir. Medicine, 98(10), e14828. https://doi.org/10.1097/MD.0000000000014828
   PubMed Web of Science ®Google Scholar
• Bourgi, K., Rebeiro, P. F., Turner, M., Castilho, J. L., Hulgan, T., Raffanti, S. P., Koethe, J. R., & Sterling, T. R. (2020). Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clinical Infectious Diseases, 70(7), 1267–1274. https://doi.org/10.1093/cid/ciz407
   PubMed Web of Science ®Google Scholar
• Brazilian Ministry of Health. (2018). Protocolo Clínico e Diretrizes Terapêuticas para o Manejo da Infecção pelo HIV em Adultos. Ministério da Saúde (BR). http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos
   Google Scholar
• Chang, C. C., Sheikh, V., Sereti, I., & French, M. A. (2014). Immune reconstitution disorders in patients with HIV infection: From pathogenesis to prevention and treatment. Current HIV/AIDS Reports, 11(3), 223–232. https://doi.org/10.1007/s11904-014-0213-0
   PubMed Web of Science ®Google Scholar
• Cuzin, L., Pugliese, P., Katlama, C., Bani-Sadr, F., Ferry, T., Rey, D., Lourenco, J., Bregigeon, S., Allavena, C., Reynes, J., Cabié, A., Drobacheff-Thiébaut, C., Foltzer, A., Bouiller, K., Hustache-Mathieu, L., Chirouze, C., Lepiller, Q., Bozon, F., Babre, O., … Valette, M. (2019). Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. Journal of Antimicrobial Chemotherapy, 74(3), 754–760. https://doi.org/10.1093/jac/dky497
   PubMed Web of Science ®Google Scholar
• Dacosta Dibonaventura, M., Gupta, S., Cho, M., & Mrus, J. (2012). The association of HIV/AIDS treatment side effects with health status, work productivity, and resource use. AIDS Care, 24(6), 744–755. https://doi.org/10.1080/09540121.2011.630363
   PubMed Web of Science ®Google Scholar
• De Boer, M. G. J., Van Den Berk, G. E. L., Van Holten, N., Oryszcyn, J. E., Dorama, W., Ait Moha, D., & Brinkman, K. (2016). Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. Aids (london, England), 30(18), 2831–2834. https://doi.org/10.1097/QAD.0000000000001279
   PubMed Web of Science ®Google Scholar
• Fernandez-Fernandez, C., Lázaro-Bengoa, E., Fernández-Antón, E., Quiroga-González, L., & Montero Corominas, D. (2020). Quantity is not enough: Completeness of suspected adverse drug reaction reports in Spain—differences between regional pharmacovigilance centres and pharmaceutical industry. European Journal of Clinical Pharmacology, 76(8), 1175–1181. https://doi.org/10.1007/s00228-020-02894-0
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Brasil Ltda. (2019). Tivicay 50 mg (package insert). http://www.anvisa.gov.br/datavisa/fila_bula/frmVisualizarBula.asp?pNuTransacao=24633662016&pIdAnexo=4000318
   Google Scholar
• Gould, J. B. (1999). Vital records for quality improvement. Pediatrics, 103(1 Suppl E), 278–290. https://doi.org/10.1542/peds.103.SE1.278
   PubMedGoogle Scholar
• Hill, A., Waters, L., & Pozniak, A. (2019). Are new antiretroviral treatments increasing the risks of clinical obesity? Journal of Virus Eradication, 5(1), 41–43. https://doi.org/10.1016/S2055-6640(20)30277-6
   PubMed Web of Science ®Google Scholar
• Hoffmann, C., & Llibre, J. M. (2019). Neuropsychiatric adverse events with Dolutegravir and other integrase strand transfer inhibitors. AIDS Reviews, 21(1), 4–10. https://doi.org/10.24875/AIDSRev.19000023
   PubMed Web of Science ®Google Scholar
• Hoffmann, C., Welz, T., Sabranski, M., Kolb, M., Wolf, E., Stellbrink, H. J., & Wyen, C. (2017). Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Medicine, 18(1), 56–63. https://doi.org/10.1111/hiv.12468
   PubMed Web of Science ®Google Scholar
• Hogan, W. R., & Wagner, M. M. (1997). Accuracy of data in computer-based patient records. Journal of the American Medical Informatics Association, 4(5), 342–355. https://doi.org/10.1136/jamia.1997.0040342
   PubMed Web of Science ®Google Scholar
• Khalili, M., Mesgarpour, B., Sharifi, H., Daneshvar Dehnavi, S., & Haghdoost, A. A. (2020). Interventions to improve adverse drug reaction reporting: A scoping review. Pharmacoepidemiology and Drug Safety, 29(9), 965–992. https://doi.org/10.1002/pds.4966
   PubMed Web of Science ®Google Scholar
• Manzardo, C., Guardo, A. C., Letang, E., Plana, M., Gatell, J. M., & Miro, J. M. (2015). Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: A comprehensive review. Expert Review of Anti-Infective Therapy, 13(6), 751–767. https://doi.org/10.1586/14787210.2015.1029917
   PubMed Web of Science ®Google Scholar
• MedDRA Maintenance and Support Services Organization. (2020). Medical dictionary for regulatory activities—MedDRA v23.0. http://www.meddramsso.com/
   Google Scholar
• Menard, A., Meddeb, L., Tissot-Dupont, H., Ravaux, I., Dhiver, C., Mokhtari, S., Tomei, C., Brouqui, P., Colson, P., & Stein, A. (2017). Dolutegravir and weight gain: An unexpected bothering side effect? Aids (london, England), 31(10), 1499–1500. https://doi.org/10.1097/QAD.0000000000001495
   PubMed Web of Science ®Google Scholar
• Mendes, J. C., Bonolo, P. F., Ceccato, M., Costa, J. O., Reis, A., Dos Santos, H., & Silveira, M. R. (2018). Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy. European Journal of Clinical Pharmacology, 74(8), 1077–1088. https://doi.org/10.1007/s00228-018-2472-y
   PubMed Web of Science ®Google Scholar
• Mofenson, L. M., Pozniak, A. L., Wambui, J., Raizes, E., Ciaranello, A., Clayden, P., Ehrenkranz, P., Fakoya, A., Hill, A., Khoo, S., Mahaka, I., Modi, S., Moore, C., Phillips, A., Siberry, G., Sikwese, K., Thorne, C., Watts, H. D., Doherty, M., & Ford, N. P. (2019). Optimizing responses to drug safety signals in pregnancy: The example of dolutegravir and neural tube defects. Journal of the International AIDS Society, 22(7), e25352. https://doi.org/10.1002/jia2.25352
   PubMed Web of Science ®Google Scholar
• Molina, J.-M., Clotet, B., van Lunzen, J., Lazzarin, A., Cavassini, M., Henry, K., Kulagin, V., Givens, N., de Oliveira, C. F., & Brennan, C. (2015). Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. The Lancet HIV, 2(4), e127–e136. https://doi.org/10.1016/S2352-3018(15)00027-2
   PubMed Web of Science ®Google Scholar
• Patel, D. A., Snedecor, S. J., Tang, W. Y., Sudharshan, L., Lim, J. W., Cuffe, R., Pulgar, S., Gilchrist, K. A., Camejo, R. R., Stephens, J., Nichols, G., & Sluis-Cremer, N. (2014). 48-Week efficacy and safety of Dolutegravir relative to commonly used third agents in treatment-naive HIV-1–infected patients: A systematic review and network meta-analysis. PLoS ONE, 9(9), e105653. https://doi.org/10.1371/journal.pone.0105653
   PubMed Web of Science ®Google Scholar
• Romero, D. E., & Cunha, C. B. d. (2006). Avaliação da qualidade das variáveis sócio-econômicas e demográficas dos óbitos de crianças menores de um ano registrados no Sistema de Informações sobre Mortalidade do Brasil (1996/2001). Cadernos de Saúde Pública, 22(3), 673–681. https://doi.org/10.1590/S0102-311X2006000300022
   PubMedGoogle Scholar
• Solomon, F. B., Angore, B. N., Koyra, H. C., Tufa, E. G., Berheto, T. M., & Admasu, M. (2018). Spectrum of opportunistic infections and associated factors among people living with HIV/AIDS in the era of highly active anti-retroviral treatment in Dawro Zone hospital: A retrospective study. BMC Research Notes, 11(1), 604. https://doi.org/10.1186/s13104-018-3707-9
   PubMedGoogle Scholar
• Uppsala Monitoring Centre. (2020a). Vigibase. World Health Organization. https://www.who-umc.org/vigibase/vigibase/
   Google Scholar
• Uppsala Monitoring Centre. (2020b). Vigiaccess. World Health Organization. http://www.vigiaccess.org/
   Google Scholar
• van De Ven, N. S., Pozniak, A. L., Levi, J. A., Clayden, P., Garratt, A., Redd, C., Mofenson, L. M., & Hill, A. (2020). Analysis of pharmacovigilance databases for Dolutegravir safety in pregnancy. Clinical Infectious Diseases, 70(12), 2599–2606. https://doi.org/10.1093/cid/ciz684
   PubMed Web of Science ®Google Scholar
• Walmsley, S., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, E., Khuong-Josses, M. A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., Roth, N., Wong, D., Granier, C., Wynne, B., & Pappa, K. (2015). Brief report: Dolutegravir plus Abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes, 70(5), 515–519. https://doi.org/10.1097/QAI.0000000000000790
   PubMed Web of Science ®Google Scholar
• Weldegebreal, T., Ahmed, I., Muhiye, A., Belete, S., Bekele, A., & Kaba, M. (2018). Magnitude of opportunistic diseases and their predictors among adult people living with HIV enrolled in care: National level cross sectional study, Ethiopia. BMC Public Health, 18(1), 820. https://doi.org/10.1186/s12889-018-5733-x
   PubMedGoogle Scholar
• WHO. World Health Organization. (2002). The importance of pharmacovigilance. Safety monitoring of medicinal products. World Health Organization. https://apps.who.int/medicinedocs/en/d/Js4893e/
   Google Scholar
• WHO. World Health Organization. (2019). Update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1
   Google Scholar
• WHO. World Health Organization Collaborating Centre for Drug Statistics Methodology. (2020). ATC/DDD Index2020. https://www.whocc.no/atc_ddd_index/
   Google Scholar
• Yombi, J. C. (2018). Dolutegravir neuropsychiatric adverse events: Specific drug effect or class effect. AIDS Reviews, 20(1), 14–26. http://www.ncbi.nlm.nih.gov/pubmed/29628511. https://doi.org/10.24875/AIDSRev.M17000013
   PubMed Web of Science ®Google Scholar
• Zash, R., Holmes, L., Diseko, M., Jacobson, D. L., Brummel, S., Mayondi, G., Isaacson, A., Davey, S., Mabuta, J., Mmalane, M., Gaolathe, T., Essex, M., Lockman, S., Makhema, J., & Shapiro, R. L. (2019). Neural-tube defects and antiretroviral treatment regimens in Botswana. New England Journal of Medicine, 381(9), 827–840. https://doi.org/10.1056/NEJMoa1905230
   PubMed Web of Science ®Google Scholar